NTRODUCTION Sample Clauses

NTRODUCTION. The adenosine receptor is a member of the rhodopsin-like family of G protein-coupled receptors (GPCRs). In human, there are 4 subtypes of adenosine receptors: X0, X0X, X0X, and A3. Among them, the A2B subtype is implied in atherosclerosis of smooth muscle cells, in mast cell activation in asthma, resulting in bronchoconstriction, in intestinal (dys)function, and in dilation of certain vascular beds (Feoktistov et al., 1998; Xxxxxxx and Xxxxxxxxx, 1998; Xxxxxxx, 2005; Xxxx et al., 2005). Despite extensive efforts, structural information on GPCRs is still scarce. To date, two crystal structures are available, that of the inactive state of bovine rhodopsin (Xxxxxxxxxx et al., 2000) and, very recently, of the human þ2 adrenergic receptor (Xxxxxxxx et al., 2007; Xxxxxxxxx et al., 2007; Xxxxxxxxx et al., 2007). Until now the structure of bovine rhodopsin has been used as a template to build homology models for GPCRs (Xxxxxxxx et al., 2003; Xxxx et al., 2006; Xxxxxxx and Xxxx, 2006; Xxxxx et al., 2006). The availability of the þ2-adrenergic receptor structure enabled us to build and compare two homology models of the human adenosine A2B receptors. Rhodopsin-like GPCRs (class A GPCRs) share a large number of conserved sequence patterns. For example, the most conserved residues in each transmembrane (TM) helix are: N1.50, D2.50, R3.50, W4.50, P5.50, P6.50, and P7.50, following the numbering scheme introduced by Xxxxxxxxxxx and Xxxxxxxxx (1995). These patterns are easily identified and used for multiple sequence alignment of rhodopsin-like GPCRs to allow sequence comparison and model building (Xxxxxxxxxx et al., 2003). Highly conserved patterns imply an important structural and/or functional role. Several conserved patterns have been identified among class A GPCRs: a disulfide bridge formed by the two Cys residues located in extracellular loop 2 (IL2) and at the beginning of TM3 (Xxxx et al., 2005); salt bridges between TM3 and TM6 or TM1 and TM7 (Xxx et al., 1997; Xxxxxxxxxxx et al., 2001); the DRY/ERY motif at the end of TM3 (Alewijnse et al., 2000); CWxP in TM 6 (Xxx et al., 2002; Xxxxxxxx et al., 2004); and an extended motif consisting of the NPxxY motif in TM 7 with the F in TM8 5 or 6 amino acids downstream of the NPxxY motif (Xxxxxxxx et al., 2001; Xxxxxx et al., 2005; Xxxxxxxxxx, et al., 2003) This NPxxY motif is highly conserved and is part of the NxxxNPxxY motif. In our previous study (Xxxxxxx et al., 2004a), we applied random mutagenesis followed by funct...
Sample 1
AutoNDA by SimpleDocs
NTRODUCTION. Upon implementation of LNP, both Parties agree to conform and provide such LNP pursuant to FCC regulations and compliance with the Industry Forum. To the extent consistent with the FCC and Industry rules as amended from time to time, the requirements for LNP shall include the following:
Sample 1
NTRODUCTION. Many studies have noted a higher prevalence of psychiatric morbidity in patients with epilepsy compared with normal controls -9 Reviews of the relevant literature suggest that mood and anxiety disorders are the most frequently diagnosed psy- chiatric disorders in patients with epilepsy 0-13. Also, an increased prevalence of per- sonality (disorder) traits or disorders is frequently found in these patients 4-16 Traditionally, temporal lobe epilepsy (TLE) is considered to present a relatively specific risk factor, notably for affective disorders, because of the major involvement of the limbic system in both seizure generation in TLE and in the regulation of af- fect and mood. Numerous studies have reported an increased rate of psychiatric disturbances in patients with TLE, compared to patients with other types of epilepsy 1,2,5,14,17-26. Other studies, however, failed to document such an association between TLE and psychiatric symptoms 6,9,27-4 . The laterality of the seizure focus has also been considered as a potential risk factor for psychiatric illness in epilepsy. Some authors emphasize the role of the right hemisphere 42,43, which is suggested to have more extensive limbic connections than the left hemisphere, whereas the majority of the studies implicate the left hemisphere 5,26,44-48, or find no effect of lateralization at all 32,35,37,38,49-54. Although there is support for the association between epilepsy and psychiatric disorders, the empirical evidence for a specific association between the localisation and lateralization of the epileptogenic zone in partial epilepsy and psy- chiatric morbidity remains equivocal. Both, methodological and theoretical factors appear to account for these discrep- ant findings. For psychiatric assessment, a variety of diagnostic instruments is used, ranging from predominantly subjective self-reporting questionnaires to objective and reliable diagnostic tests. Some authors use cut-off scores to classify the sub- jects, whereas others use mean scores. Psychiatric findings from these studies are thus difficult to compare. The same can be said for the selection of patients with epilepsy who were investi- gated, and the control subjects. Several studies fail to define clear diagnostic xxxxx- ria for epilepsy and/or psychiatric disorders and their selection criteria, and precise definitions of epilepsy subgroups are often unclear or not provided for at all. Early studies on the prevalence of psychiatric syndromes in epilep...
Sample 1
NTRODUCTION. 1.1 Parties This Settlement Agreement is entered by and between Center for Advanced Public Awareness, Inc. CAPA ) and Ground Up International Ground Up ), with CAPA and Ground Up CAPA is a California nonprofit corporation dedicated to protecting the environment, improving human health, and promoting environmentally sound practices. Ground Up supplied the footwear (flip-flops) referenced in this Settlement Agreement to Wal-Mart Stores, Inc. ( Wal-Mart ), the entity named in CAPA September 17, 2017, 60-Day Notice of Violation. As the manufacturer of the products covered by this Settlement Agreement, Ground Up is stepping in to resolve the alleged violations at issue. General Allegations 1.2 CAPA alleges that Wal-Mart sells vinyl/PVC footwear containing di-butyl phthalate ( DBP ), that is manufactured, sold, distributed for sale, or otherwise supplied to Wal-Mart by Ground Up. DBP is listed pursuant to Proposition 65 as a chemical known to cause birth defects or other reproductive harm. 1.3 Covered Products Defined Covered as footwear (flip-flops) that contain DBP and that are sold or distributed for sale in California by Ground Up and those in its supply chain including, but not limited to, Wal-Mart. Covered Products include, but are not limited to, the Red Strap Flip-Flop with Stars and Stripes Image, SKU No. 0842088102234 identified in CAPA .
Sample 1
NTRODUCTION. The District shall comply with the following travel and per diem reimbursement requirements, as well as all other reimbursement requirements set forth in general or special law and specifically Section 112.061 Florida Statute, as may be amended: A. All travelers requiring advance approval shall originate the Permission to Travel Form requesting approval which shall include such items as the name of the traveler, the dates and purpose of travel, and estimated cost. The Fire Chief must authorize this Form. Travel approval for the Fire Chief shall be authorized by the Board of Fire Commissioners. Travel approval for a Commissioner shall be authorized by the Board of Fire Commissioners. B. For reimbursement, the traveler must prepare a Travel Voucher Form itemizing all expenses incurred, attach to it all required receipts, and submit to the Assistant Fire Chief of Administrative for approval. Approval for the Fire Chief’s reimbursement shall be authorized by the Board of Fire Commissioners if reimbursement exceeds $500.00 in any given month. If reimbursement is less than $500.00 in any given month, authorization shall be given by the Chairman or Treasurer of the Board of Fire Commissioners. There will be no reimbursement of expenses without the travel voucher. The Accounts Payable/Receivable Accountant reimburses the traveler for any travel expenses incurred not included in an advance. If the voucher exceeds any advance, the traveler must return the excess to the District. C. The type of travel to be incurred governs the rates of travel reimbursement. If the travel requires overnight stay, the traveler is allowed a per diem allowance or subsistence allowance plus lodging; if the travel does not require overnight stay, only subsistence for meals allowed shall be reimbursed. Other expenses to be reimbursed include convention fees, transportation costs (taxi, bus fare, etc.), tolls, parking, and mileage (if traveler is using privately owned vehicle)
Sample 1

Related to NTRODUCTION

  • Introduction The Texas Health and Human Services Commission ("HHSC") and the Contractor named in Section I (HHSC and Contractor may be referenced in this document collectively as the “Parties” and individually as the “Party") hereby enter into this Community Services Contract - Provider Agreement (the “Contract”) for the provision of services under the Contract type specified in Section I for the considerations set forth herein. The Contract Begin Date specified in Section I is not valid until this Contract is signed by both parties.

  • Introduction and Background The purpose of this Schedule 2 (Contract Services and Contract Supplies) is to set out the characteristics of the Contract Services and/or Contract Supplies (as the case may be) and Funding that the Provider will be required to make available to all Contracting Authorities in relation to Lot 1 and/or Lot 2 (as the case may be) and to provide a description of what the Contract Services and/or Contract Supplies (as the case may be) and Funding will entail.

  • Production Lessee shall, subject to applicable laws, regulations and orders, operate and produce all xxxxx upon the leased land so long as the same are capable of producing in paying quantities, and shall operate the same so as to produce at a rate commensurate with the rate of production of xxxxx on adjoining lands within the same field and within the limits of good engineering practice, except for such times as there exist neither market nor storage therefore, and except for such limitations on, or suspensions of, production as may be approved in writing by Lessor. Lessee shall be responsible for adequate site security on all producing properties.

  • Introducer 21.1 In cases where the Client is introduced to the Company through a third person (“Introducer”), the Client acknowledges that the Company is not responsible or accountable for the conduct and/or representations of the Introducer and the Company is not bound by any separate agreements entered into between the Client and the Introducer. 21.2 The Client acknowledges and confirms that his agreement or relationship with the Introducer may result in additional costs, since the Company may be obliged to pay commission fees or charges to the Introducer.

  • Project Implementation The Borrower shall:

  • Fabrication Making up data or results and recording or reporting them.

  • Investigational Services This plan covers certain experimental or investigational services as described in this section. This plan covers clinical trials as required under R.I. General Law § 27-20-60. An approved clinical trial is a phase I, phase II, phase III, or phase IV clinical trial that is being performed to prevent, detect or treat cancer or a life-threatening disease or condition. In order to qualify, the clinical trial must be: • federally funded; • conducted under an investigational new drug application reviewed by the Food and Drug Administration (FDA); or • a drug trial that is exempt from having such an investigational new drug application. To qualify to participate in a clinical trial: • you must be determined to be eligible, according to the trial protocol; • a network provider must have concluded that your participation would be appropriate; and • medical and scientific information must have been provided establishing that your participation in the clinical trial would be appropriate. If a network provider is participating in a clinical trial, and the trial is being conducted in the state in which you reside, you may be required to participate in the trial through the network provider. Coverage under this plan includes routine patient costs for covered healthcare services furnished in connection with participation in a clinical trial. The amount you pay is based on the type of service you receive. Coverage for clinical trials does not include: • the investigational item, device, or service itself; • items or services provided solely to satisfy data collection and that are not used in the direct clinical management; or • a service that is clearly inconsistent with widely accepted standards of care.

  • Introduction and Purpose Introduction • Neighbourhood Development Plans • Neighbourhood Development Orders

  • Culture History and past behavior;

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!